Advertisement
Table 3 Univariate and multivariate analysis for local control and overall survival according to patient and tumor characteristics
| Univariate | Multivariate | |||
|---|---|---|---|---|
| HR (CI) | p-value | HR (CI) | p-value | |
| Local control | ||||
| Prior CTxa | 2.19 (1.23–3.91) | 0.008 | 2.19 (1.18–4.06) | 0.13 |
| Histology (CRC) | 1.99 (1.31–3.04) | 0.001 | 1.71 (1.04–2.80) | 0.03 |
| Histology (BCa) | 0.53 (0.25–1.13) | 0.10 | 0.45 (0.19–1.02) | 0.06 |
| Histology (NSCLC) | 0.86 (0.26–2.85) | 0.81 | 0.67 (0.19–2.35) | 0.54 |
| GTV Volumec | 1.004 (1.002–1.005) | < 0.001 | – | |
| PTV Volumec | 1.002 (1.001–1.003) | < 0.001 | 1.001 (1.00–1.002) | 0.003 |
| BED Isocenterc | 0.993 (0.989–0.997) | < 0.001 | 0.99 (0.98–1.00) | 0.002 |
| BED prescriptionc | 0.72 (0.51–1.01) | 0.003 | 1.00 (0.99–1.01) | 0.970 |
| Advanced Motion managementa | 0.46 (0.29–0.72) | < 0.001 | 0.57 (0.33–0.96) | 0.04 |
| Before 2003a | 1.50 (1.04–2.16) | 0.031 | 1.02 (0.61–1.70) | 0.932 |
| Overall survival | ||||
| KIc | 0.69 (0.51–0.94) | 0.02 | 0.74 (0.53–0.98) | 0.06 |
| Gender | 0.80 (0.63–1.01) | 0.06 | 0.76 (0.54–1.06) | 0.10 |
| Histology (CRC) | 0.61 (0.46–0.79) | < 0.001 | 0.64 (0.45–0.92) | 0.01 |
| Histology (BCa) | 0.52 (0.36–0.76) | < 0.001 | 0.60 (0.36–0.99) | 0.05 |
| Histology (NSCLC) | 1.42 (0.87–2.33) | 0.16 | 1.14 (0.64–2.07) | 0.65 |
| Prior CTxa | 0.91 (0.65–1.27) | 0.58 | 1.17 (0.76–1.80) | 0.47 |
| Extrahepatic statusb | 0.81 (0.60–1.1) | 0.18 | 0.83 (0.49–1.43) | 0.52 |
| Solitarya | 0.73 (0.57–0.92) | 0.007 | 1.12 (0.61–2.03) | 0.72 |
| # of liver metastases (1 vs. 2–4) | 0.94 (0.72–1.23) | 0.65 | 0.80 (0.52–1.23) | 0.32 |
| GTV Volumec | 1.003 (1.002–1.004) | < 0.001 | – | |
| PTV Volumec | 1.002 (1.001–1.002) | < 0.001 | 1.002 (1.001–1.003) | < 0.001 |
| Local recurrence after SBRTa | 0.88 (0.68–1.51) | 0.36 | 0.82 (0.56–1.19) | 0.29 |
| BED isocenterc | 0.997 (0.994–1.00) | 0.06 | 1.00 (0.99–1.004) | 0.97 |
